Clinical Trials Logo
  1. Home
  2. Synovial Sarcoma
  3. NCT02683148

DHEA in Synovial Sarcoma Patients

Synovial Sarcoma Clinical Trial

Official title:
A Phase I/II Clinical Trial of Dose-Escalating DHEA in Synovial Sarcoma Patients

Clinical Trial Summary

DHEA is a natural allosteric inhibitor of glucose-6-phosphate dehydrogenase (G6PD). G6PD is a key regulatory enzyme for the survival of synovial sarcoma. The investigators postulate that they can inhibit the production of NADPH in synovial sarcoma and cause cell death by using a naturally occurring G6PD inhibitor.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02683148
Study type Interventional
Source Washington University School of Medicine
Contact
Status Terminated
Phase Phase 1
Start date September 13, 2016
Completion date April 4, 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Terminated NCT01957709 - Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Early Phase 1
Not yet recruiting NCT06456359 - Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor Phase 2
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT01674101 - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy N/A
Completed NCT03250325 - Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma Phase 1/Phase 2
Recruiting NCT06094101 - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Phase 1/Phase 2
Terminated NCT03520959 - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) Phase 3
Recruiting NCT05642455 - SPEARHEAD-3 Pediatric Study Phase 1/Phase 2
Active, not recruiting NCT04420975 - Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Phase 1
Recruiting NCT02983539 - Detection of Circulating Tumor Cells in Patients With Sarcomas
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Active, not recruiting NCT03132922 - MAGE-A4ᶜ¹º³²T for Multi-Tumor Phase 1
Terminated NCT04145700 - CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma Phase 1/Phase 2
Completed NCT00004853 - Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy Phase 1
Suspended NCT06083883 - Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 Phase 1
Terminated NCT05355753 - A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors Phase 1/Phase 2
Withdrawn NCT05116800 - Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Phase 2
Recruiting NCT03638206 - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies Phase 1/Phase 2